Differences in Pulmonary Function Improvement After Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Dec 11

PMID 36498738

Authors

Wei-Chun Huang

Chih-Yu Chen

Wei-Chih Liao

Biing-Ru Wu

Wei-Chun Chen

Chih-Yen Tu

Chia-Hung Chen

Wen-Chien Cheng

Affiliations

Soon will be listed here.

Abstract

This real-world study evaluated the efficacy of once-daily long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) for improving lung function in patients with chronic obstructive pulmonary disease (COPD). Patients with COPD who were treated with once-daily LABA/LAMA FDCs for 12 months were included. We evaluated their lung function improvement after 12 months of treatment with different LABA/LAMA FDCs. A total of 198 patients with COPD who were treated with once-daily LABA/LAMA FDCs were analyzed. A total of 114 patients were treated with umeclidinium/vilanterol (UMEC/VIL); 34 patients were treated with indacaterol/glycopyrronium (IND/GLY); and 50 patients were treated with tiotropium/olodaterol (TIO/OLO). The forced expiratory volume in 1 s (FEV1) was significantly increased in the patients treated with all three once-daily FDCs (55.2% to 60.9%, p = 0.012 for UMEC/VIL, 58.2% to 63.6%, p = 0.023 for IND/GLY, and 54.1% to 57.7%, p = 0.009 for TIO/OLO). The treatment of COPD patients with TIO/OLO resulted in a significant improvement in both forced vital capacity (FVC%) (71.7% to 77.9%, p = 0.009) and residual volume (RV%) (180.1% to 152.5%, p < 0.01) compared with those treated with UMEC/VIL (FVC%: 75.1% to 81.5%, p < 0.001; RV%:173.8% to 165.2%, p = 0.231) or IND/GLY (FVC%: 73.9% to 79.3%, p = 0.08; RV%:176.8% to 168.3%, p = 0.589). Patients treated with UMEC/VIL or TIO/OLO showed significant improvement in FVC. In addition, those receiving TIO/OLO also showed significant improvement in RV reduction.

Citing Articles

PREVAX: A Phase I Clinical Trial of an EGF-Based Vaccine in Moderate-to-Severe COPD Patients.

Hernandez Reyes J, Santos Morales O, Hernandez Moreno L, Pino Alfonso P, Neninger Vinageras E, Knigths Montalvo J Vaccines (Basel). 2024; 12(8).

PMID: 39203959 PMC: 11359286. DOI: 10.3390/vaccines12080833.

References

van der Palen J, Thomas M, Chrystyn H, Sharma R, van der Valk P, Goosens M . A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices. NPJ Prim Care Respir Med. 2017; 27:17001. PMC: 5375387. DOI: 10.1038/npjpcrm.2017.1. View

Moretz C, Bengtson L, Sharpsten L, Koep E, Le L, Tong J . Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol. Int J Chron Obstruct Pulmon Dis. 2019; 14:2047-2060. PMC: 6732570. DOI: 10.2147/COPD.S213520. View

Pisi R, Aiello M, Zanini A, Tzani P, Paleari D, Marangio E . Small airway dysfunction and flow and volume bronchodilator responsiveness in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015; 10:1191-7. PMC: 4480584. DOI: 10.2147/COPD.S82509. View

Kerwin E, Ferguson G, Sanjar S, Goodin T, Yadao A, Fogel R . Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies. Lung. 2017; 195(6):739-747. DOI: 10.1007/s00408-017-0055-9. View

Ferguson G, Karpel J, Bennett N, Clerisme-Beaty E, Gronke L, Voss F . Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies. NPJ Prim Care Respir Med. 2017; 27(1):7. PMC: 5434778. DOI: 10.1038/s41533-016-0002-x. View

Schlueter M, Gonzalez-Rojas N, Baldwin M, Groenke L, Voss F, Reason T . Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis. Ther Adv Respir Dis. 2016; 10(2):89-104. PMC: 5933564. DOI: 10.1177/1753465815624612. View

Fortis S, Comellas A, Make B, Hersh C, Bodduluri S, Georgopoulos D . Combined Forced Expiratory Volume in 1 Second and Forced Vital Capacity Bronchodilator Response, Exacerbations, and Mortality in Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2019; 16(7):826-835. PMC: 6600841. DOI: 10.1513/AnnalsATS.201809-601OC. View

Singh D . Small Airway Disease in Patients with Chronic Obstructive Pulmonary Disease. Tuberc Respir Dis (Seoul). 2017; 80(4):317-324. PMC: 5617847. DOI: 10.4046/trd.2017.0080. View

Kakavas S, Kotsiou O, Perlikos F, Mermiri M, Mavrovounis G, Gourgoulianis K . Pulmonary function testing in COPD: looking beyond the curtain of FEV1. NPJ Prim Care Respir Med. 2021; 31(1):23. PMC: 8105397. DOI: 10.1038/s41533-021-00236-w. View

10.

Hanania N, Celli B, Donohue J, Martin U . Bronchodilator reversibility in COPD. Chest. 2011; 140(4):1055-1063. DOI: 10.1378/chest.10-2974. View

11.

Dean J, Kolsum U, Hitchen P, Gupta V, Singh D . Clinical characteristics of COPD patients with tidal expiratory flow limitation. Int J Chron Obstruct Pulmon Dis. 2017; 12:1503-1506. PMC: 5446959. DOI: 10.2147/COPD.S137865. View

12.

Anzueto A, Vogelmeier C, Kostikas K, Mezzi K, Fucile S, Bader G . The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD. Int J Chron Obstruct Pulmon Dis. 2017; 12:1325-1337. PMC: 5422319. DOI: 10.2147/COPD.S133307. View

13.

Sion K, Huisman E, Punekar Y, Naya I, Ismaila A . A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β-Agonist (LABA) Combinations in COPD. Pulm Ther. 2020; 3(2):297-316. PMC: 6964204. DOI: 10.1007/s41030-017-0048-0. View

14.

Newton M, ODonnell D, Forkert L . Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest. 2002; 121(4):1042-50. DOI: 10.1378/chest.121.4.1042. View

15.

Rabe K, Hurd S, Anzueto A, Barnes P, Buist S, Calverley P . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007; 176(6):532-55. DOI: 10.1164/rccm.200703-456SO. View

16.

Calverley P, Albert P, Walker P . Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations. Lancet Respir Med. 2014; 1(7):564-73. DOI: 10.1016/S2213-2600(13)70086-9. View

17.

Ramadan W, Sarkis A . Patterns of use of dry powder inhalers versus pressurized metered-dose inhalers devices in adult patients with chronic obstructive pulmonary disease or asthma: An observational comparative study. Chron Respir Dis. 2017; 14(3):309-320. PMC: 5720234. DOI: 10.1177/1479972316687209. View

18.

Rodriguez-Carballeira M, Heredia J, Rue M, Quintana S, Almagro P . The bronchodilator test in chronic obstructive pulmonary disease: interpretation methods. Respir Med. 2006; 101(1):34-42. DOI: 10.1016/j.rmed.2006.04.018. View

19.

Singh D, Agusti A, Anzueto A, Barnes P, Bourbeau J, Celli B . Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J. 2019; 53(5). DOI: 10.1183/13993003.00164-2019. View

20.

Feldman G, Sousa A, Lipson D, Tombs L, Barnes N, Riley J . Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study. Adv Ther. 2017; 34(11):2518-2533. PMC: 5702366. DOI: 10.1007/s12325-017-0626-4. View